January 09, 2007 10:19 ET

Taglich Brothers Initiates Coverage on Pressure BioSciences, Inc.

NEW YORK, NY -- (MARKET WIRE) -- January 9, 2007 -- Taglich Brothers, Inc. announces it initiated coverage of Pressure BioSciences, Inc. (NASDAQ: PBIO).

Pressure BioSciences (NASDAQ: PBIO), headquartered in West Bridgewater, MA, has developed Pressure Cycling Technology, which uses cycles of hydrostatic pressure to control biomolecular interactions. This technology can be applied in genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics and protein purification. The company markets its Barocycler™ system and PULSE tube sample containers to research laboratories in academia, government and industry.

The complete 19-page report is available at

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

* The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the above-mentioned report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock Pressure BioSciences, Inc. All research issued by Taglich Brothers, Inc. is based on public information. The company paid a monetary engagement fee of $19,500 (USD) for the first year of creation and dissemination of research reports and will pay a monthly monetary fee of $1,750 (USD) to Taglich Brothers, Inc. for these services after the first year.

Contact Information